GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences (GILD) Business News

Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Business Wire

8:30 AM | Wednesday | Sep 16, 2026

news photo
Loading...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.

Read full article redirect
8:30 AM | Wednesday | Sep 16, 2026

Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while the.

Read full article arrow
News Thumbnail
11:10 AM | Tuesday | Sep 15, 2026

Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO's Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led effor.

Read full article arrow
News Thumbnail
5:47 PM | Thursday | Aug 27, 2026

U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed.
Bixlenvo is now the first and only STR option for virologically suppressed people with HIV who are on complex regimens and unable to take currently available STRs. This novel HIV t.

Read full article arrow
News Thumbnail
6:31 AM | Monday | Aug 24, 2026

European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 with a combined positive sc.

Read full article arrow
News Thumbnail
9:41 PM | Tuesday | Aug 4, 2026

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Please replace the release with the following corrected version due to a change in the "PRODUCT SALES SUMMARY" table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million). The updated release reads: GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Yea.

Read full article arrow
News Thumbnail
5:07 PM | Tuesday | Aug 4, 2026

AHF Crowns Gilead Corporate Welfare King

Business Wire

LOS ANGELES--(BUSINESS WIRE)-- #AHFcares--AHF Crowns Gilead Corporate Welfare King.

Read full article arrow
News Thumbnail
4:01 PM | Tuesday | Aug 4, 2026

Gilead Sciences Announces Second Quarter 2026 Financial Results

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026. “Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Dan.

Read full article arrow
News Thumbnail
6:26 AM | Friday | Jul 24, 2026

CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab), for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received.

Read full article arrow
News Thumbnail